文献速递前列腺癌

前列腺多参数磁共振阴性在临床实践中的作用:是否仍需活检?

Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary?
PubMed 文献 · Urology · 2016-11-11

该研究回顾性分析了2012年1月至2015年12月在本机构接受前列腺多参数磁共振(mpMRI)且无可疑病灶或PI-RADS 1-2分的84例男性,均行标准模板经直肠超声引导前列腺活检。结果显示活检初治者高级别前列腺癌(Gleason评分≥7)检出率为10.3%(阴性预测值89.7%),既往活检阴性者为16.7%(阴性预测值83.3%),主动监测者为13.3%(阴性预测值86.6%)。多因素分析中,前列腺癌预防试验风险计算器(PCPTRC)估计的高级别前列腺癌风险(连续变量)是活检高级别前列腺癌的显著预测因子(比值比1.01,P<.01)。结论认为,常规临床解读的mpMRI阴性者仍存在Gleason评分≥7前列腺癌的显著风险,独立于活检指征,应仍推荐行标准模板经直肠超声前列腺活检,尤其是PCPTRC估计高级别前列腺癌风险较高的患者。

要点

  • mpMRI阴性者活检高级别前列腺癌检出率:活检初治10.3%、既往活检阴性16.7%、主动监测13.3%。
  • PCPTRC估计高级别前列腺癌风险(连续变量)是活检高级别前列腺癌的显著预测因子(比值比1.01,P<.01)。
  • 作者建议mpMRI阴性者仍应推荐标准模板经直肠超声前列腺活检,尤其是PCPTRC估计高风险者。

核心结论

  • 常规临床解读的mpMRI阴性者行标准12区域模板活检仍存在Gleason评分≥7前列腺癌的显著风险,独立于活检指征。
  • 作者建议mpMRI阴性者仍应推荐标准模板经直肠超声前列腺活检,尤其是PCPTRC估计高级别前列腺癌风险较高的患者。

研究设计与样本

  • 回顾性分析本机构前瞻性维护的连续男性数据库,纳入2012年1月至2015年12月接受前列腺mpMRI且由学术放射科医师临床实践解读的男性。
  • 共84例无任何磁共振可疑区域(按既往机构分类)或PI-RADS 1-2分病灶的男性接受标准模板经直肠超声引导前列腺活检。

主要发现

  • 活检初治患者高级别前列腺癌(Gleason评分≥7)检出率为10.3%,阴性预测值89.7%。
  • 既往活检阴性患者高级别前列腺癌检出率为16.7%,阴性预测值83.3%。
  • 主动监测患者高级别前列腺癌检出率为13.3%,阴性预测值86.6%。
  • 多因素分析中,PCPTRC估计的高级别前列腺癌风险(连续变量)是活检高级别前列腺癌的显著预测因子(比值比1.01,P<.01)。

关键数值与推荐

  • mpMRI阴性定义为无任何磁共振可疑区域(按既往机构分类)或PI-RADS 1-2分病灶。
  • 高级别前列腺癌定义为Gleason评分≥7。
  • 活检初治者阴性预测值89.7%,既往活检阴性者阴性预测值83.3%,主动监测者阴性预测值86.6%。
  • PCPTRC估计高级别前列腺癌风险的比值比为1.01(P<.01)。

临床怎么用

  • 作者建议mpMRI阴性者仍应推荐标准模板经直肠超声前列腺活检。
  • 作者建议尤其应对PCPTRC估计高级别前列腺癌风险较高的mpMRI阴性患者推荐活检。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the negative predictive value (NPV) of multiparametric magnetic resonance imaging (mpMRI) for detection of prostate cancer (PCa) in routine clinical practice and to identify characteristics of patients for whom mpMRI fails to detect high-grade (Gleason score ≥7) disease. MATERIALS AND METHODS: We reviewed our prospectively maintained database of consecutive men who received prostate mpMRI at our institution, interpreted by a clinical practice of academic radiologists. Between January 2012 and December 2015, 84 men without any magnetic resonance imaging suspicious regions according to prior institutional classification, or with Prostate Imaging Reporting and Data System (PI-RADS) 1-2 lesions according to the PI-RADS system, underwent standard template transrectal ultrasound (TRUS)-guided prostate biopsy. Using these biopsy results, we calculated the NPV of mpMRI for the detection of PCa and identified patient risk factors for having a Gleason score ≥7 PCa on biopsy. RESULTS: High-grade PCa (Gleason score ≥7) was found on TRUS biopsy in 10.3% of biopsy-naive patients (NPV=89.7%), 16.7% of patients with previous negative biopsy (NPV=83.3%), and 13.3% of patients on active surveillance (NPV=86.6%). On multivariate analysis, the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) estimated risk for high-grade PCa (as a continuous variable) was a significant predictor for high-grade PCa on biopsy (odds ratio 1.01, P < .01). CONCLUSION: Men with negative mpMRIs interpreted in a routine clinical setting have a significant risk of harboring Gleason score ≥7 PCa on a standard 12-region template biopsy, independent of indication. Standard template TRUS prostate biopsy should still be recommended for patients with negative mpMRI, particularly those with elevated PCPTRC estimated risk of high-grade PCa.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Wang RS, Kim EH, Vetter JM, et al. Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary? Urology. 2016. PMID: 27845218. doi:10.1016/j.urology.2016.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。